Betting on Tech
Health Care: Drugs
Omeros Corporation (OMER: NASDAQ)
$5.18 0.21 | 4.23%
06/18/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 1.52M | 4.00M | 3.28M | 820.00K |
| Receivables | 1.93M | 876.00K | 1.48M | 248.00K |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 24.70M | 25.95M | 43.75M | 60.66M |
| Property, Plant & Equipment, Gross | 2.83M | 3.22M | 3.70M | 2.72M |
| Accumulated Depreciation & Depletion | 1.79M | 2.48M | 2.08M | 1.64M |
| Property, Plant & Equipment, Net | 1.04M | 739.00K | 1.62M | 1.09M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 838.00K | 295.00K | 328.00K | 312.00K |
| Total Non-Current Assets | 1.88M | 1.03M | 1.95M | 1.40M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 26.58M | 26.98M | 45.70M | 62.06M |
| Accounts Payable | 2.63M | 2.00M | 2.40M | 2.62M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 959.00K | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 9.32M | 18.98M | 15.87M | 11.09M |
| Long Term Debt | 20.10M | 13.55M | 9.36M | 7.83M |
| Deferred Income Taxes | 3.68M | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 23.79M | 13.55M | 9.36M | 7.83M |
| Total Liabilities | 33.11M | 32.54M | 25.23M | 18.92M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | -6.53M | -5.55M | 20.47M | 43.14M |
| Common Par | 259.00K | 224.00K | 219.00K | 213.00K |
| Additional Paid In Capital | 207.79M | 170.36M | 167.84M | 161.23M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -214.58M | -176.13M | -147.59M | -118.34M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | 41.00K |
| Total Capitalization | 13.57M | 8.00M | 29.83M | 50.97M |
| Total Equity | -6.53M | -5.55M | 20.47M | 43.14M |
| Total Liabilities & Stock Equity | 26.58M | 26.98M | 45.70M | 62.06M |
| Total Common Shares Outstanding | 25.90M | 22.43M | 21.92M | 21.29M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 24.16M | 22.21M | 21.42M | 7.22M |
| Diluted Weighted Shares Outstanding | 24.16M | 22.21M | 21.42M | 7.22M |
| Number of Employees | 71 | 70 | 70 | 67 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with OMER
- Portfolio NameUser Type
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusual Vo...
Latest OMER Headlines from TheStreet
- 5 Stocks Insiders are Scooping Up 01.09.13 | 12:01 pm
- Top Insider Trades: FB LNKD SMM OMER 01.07.13 | 08:01 am
- Omeros Stock Gaps Down On Today's Open (OMER) 06.27.12 | 09:06 am
- 7 Stocks Soaring on Unusual Volume 06.08.12 | 04:06 pm
- 10 Stocks to Watch: Krispy Kreme, Omeros 04.01.11 | 01:04 pm
- Omeros Stock Gaps Down On Today's Open (OMER) 04.01.11 | 09:04 am
- Omeros, EXFO: After-Hours Trading 03.31.11 | 05:03 pm
- IPO Comeback In 2009 Sets Stage For Busy 2010 12.31.09 | 10:12 am
- Worst IPOs of 2009: Biggest Stock Flops 12.15.09 | 10:12 am
Press Releases for OMER
- Omeros To Present Additional OMS302 Clinical Data At The Annual ASCRS And ASOA Symposium And Congress - PR Newswire 04.19.13 | 07:04 am
- Omeros Files Orphan Drug Application For Treatment Of Atypical Hemolytic Uremic Syndrome With OMS721 - PR Newswire 04.17.13 | 07:04 am
- Omeros Announces That GPR17 Antagonists Improve Function In Model Of Multiple Sclerosis - PR Newswire 04.10.13 | 07:04 am
- Omeros Announces Positive OMS721 Data In Model Of Thrombotic Microangiopathy - PR Newswire 04.02.13 | 07:04 am
- Omeros To Present At The 2013 Future Leaders In The Biotech Industry Conference - PR Newswire 03.29.13 | 07:03 am
- Omeros Announces Toxicology Data That Support Advancing MASP-2 Inhibitor Into Clinical Trials - PR Newswire 03.28.13 | 07:03 am
- Omeros Announces Successful Completion Of PDE10 Phase 1 Multiple Ascending Dose Trial - PR Newswire 03.26.13 | 07:03 am
- Omeros Elucidates Mechanism Of Its PDE7 Inhibitors In Addiction - PR Newswire 03.19.13 | 07:03 am
- Omeros To Present At The Cowen And Company 33rd Annual Health Care Conference - PR Newswire 03.01.13 | 07:03 am
- Omeros Announces Toxicology Study Data From MASP-2 Inhibitor - PR Newswire 02.07.13 | 07:02 am
Partner Headlines for OMER
- Omeros Files CTA for aHUS Candidate - Analyst Blog - Zacks 05.30.13 | 12:05 am
- FDA Accepts Omeros' IND for OMS824 - Analyst Blog - Zacks 05.29.13 | 01:05 am
- Is This Biotech A Value Stock Or Value Trap? - Seeking Alpha 03.30.13 | 06:03 am
- Do You Have The Guts To Take On Cutting-Edge Biotech Like This VC? - Seeking Alpha 12.14.12 | 09:12 am
- From Earlier: Investigational New Drug Application Cleared for Omeros' Lead Compound in PDE10 Program - Benzinga 10.02.12 | 09:10 am
- Netflix REITERATED Below Average and 3 Analyst-Reiterated Ratings Starting the Week - Wall St. Cheat Sheet 07.23.12 | 04:07 am
- Market Wrap: Markets RALLY, Arena Makes HISTORY, Apple BEATS Samsung - Wall St. Cheat Sheet 06.28.12 | 09:06 am
- Ultimate Market Recap: News Corp. Makes Split Decision, RIM Looking Rough - Wall St. Cheat Sheet 06.28.12 | 08:06 am
- Omeros Eyeing Deals As Ophthalmology Drug Succeeds - Seeking Alpha 03.15.12 | 09:03 am
- UPDATE: Canaccord Upgrades Omeros; Raises PT - Benzinga 03.14.12 | 09:03 am
